Up­dat­ed: Aca­dia wins first FDA ap­proval for Rett syn­drome drug

The FDA on Fri­day ap­proved Aca­dia Phar­ma­ceu­ti­cals’ treat­ment for Rett syn­drome, a rare neu­rode­vel­op­men­tal dis­or­der, which will be sold un­der the brand name Day­bue (trofine­tide), the com­pa­ny an­nounced.

The av­er­age list price for the drug will be about $575,000 to $595,000 a year, CEO Steve Davis said on a con­fer­ence call Mon­day morn­ing. That comes from a $21.10 per mil­li­liter price that’s used for weight-based dos­ing. The com­pa­ny’s “net re­al­ized cost” will be ap­prox­i­mate­ly $375,000, he said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER